QSAR-Based Pharmacophore Optimization of 4-Aminoquinoline
Derivatives: Computational Insights into Structure-Activity Relationship
and Anticancer Potential
Jul 2026· Current Enzyme Inhibition· Vol 22· 0 citations
TL;DR
The results indicate that electronic and steric factors around the 4-aminoquinoline nucleus strongly influence anticancer activity, and the optimised pharmacophore provides a framework for designing new, more potent anticancer agents.
Abstract
Breast cancer is characterised by the uncontrolled growth of cells within
the mammary glands, which can later spread to adjacent tissues. The current treatment options include alkylating agents, intercalating agents, topoisomerase inhibitors, antimetabolites, and antimitotic drugs. Computer-aided drug design has contributed in a large way to the development of anticancer drugs. The objective of this study was to perform pharmacophore optimisation of 4-
aminoquinoline derivatives using QSARINS software for the development of QSAR models for anticancer activity.
A series of thirty-six 4-aminoquinoline derivatives was used to generate 2D and fingerprint-based QSAR models using the Genetic Algorithm-Multiple Linear Regression (GA-MLR)
method. The resulting statistical parameters and graphical data were evaluated, and models with
strong statistical performance were selected for further analysis.
The 2D QSAR model exhibited R² = 0.9757 and Q² = 0.9490, and the fingerprint-based
QSAR model displayed values of R² = 0.9884 and Q² = 0.9736. Both models showed internal robustness with limited external predictive capability.
The results indicate that electronic and steric factors around the 4-aminoquinoline nucleus strongly influence anticancer activity. The optimised pharmacophore provides a framework
for designing new, more potent anticancer agents.
The optimised pharmacophore indicates the contribution of electronegative substituents at the 7th position of the quinoline ring, along with a dimethylamino biphenyl group at the 3rd
position, for better anticancer activity. Considering the limitations of the present study, namely, limited external predictive capability, further refinement of the models would be required.
The findings from molecular docking, 500-ns molecular dynamics simulations, MM-GBSA calculations, and alanine scanning analyses collectively corroborate a stable binding mode of BTB11556 within the MPO active site, support further investigation of BTB11556 as a candidate compound associated with MPO-targeted therapeuti...
Maysoon Raed Alnajdawi, H. Wahab, Belal Alnajjar et al.· Journal of Computer-Aided Mo...· 1 citation
An integrated computational investigation of 44 hydrazide–hydrazone derivatives sharing a common 5H-chromen-5-one scaffold and evaluated for anticancer activity against HCT116 human colon carcinoma cells identifies S8 as a promising lead compound for further development as a potential anticancer agent targeting colorec...
Y. El Allouche, L. Naanaai, Youssra Ech-Chahdi et al.· Chemistry Africa· 0 citations
Light is shed on the structural prerequisites for anticancer action, which may aid in the rational development of more effective benzimidazole-based medicinal medicines, and emphasizing the significance of descriptors such as molar refractivity, partition coefficient, and related factors.
Arun Kumar Rai, Keerti Sahu, Megha Chouhan et al.· World Journal of Current Med...· 0 citations
Computational findings support the prioritization of X14 for further experimental validation in glioblastoma therapy, and generally favorable ADMET profiles were observed, hepatotoxicity alerts were predicted for all compounds, which represents an important limitation supporting the prioritization of X14.
Youssef Briach, M. Er-rajy, Jamal Elkhabchi et al.· Biointerface Research in App...· 0 citations
Breast cancer still ranks to be one of the primary causes of cancer-related death worldwide, underscoring the critical need for innovative targeted treatment agents with enhanced safety and efficacy. The current work examined Thienopyrimidinone-based derivatives as possible EGFR inhibitors for breast cancer treatment u...
Shashikant V. Bhandari, Rutuja R. Napte, S. Patil et al.· Bioorganic chemistry (Print)· 0 citations